Oncocyte Corp (NASDAQ:IMDX – Get Free Report) has been given a consensus rating of “Hold” by the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.33.
A number of brokerages have recently commented on IMDX. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price objective on shares of Oncocyte in a research note on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a research note on Monday, September 21st. Stephens reiterated an “equal weight” rating and issued a $4.00 target price on shares of Oncocyte in a research note on Wednesday. Wall Street Zen downgraded shares of Oncocyte from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Finally, BTIG Research restated a “neutral” rating on shares of Oncocyte in a research report on Wednesday.
Get Our Latest Report on Oncocyte
Oncocyte Stock Up 11.2%
Shares of IMDX stock traded up $0.18 on Thursday, hitting $1.77. The company had a trading volume of 18,269 shares, compared to its average volume of 237,178. Oncocyte has a twelve month low of $1.50 and a twelve month high of $7.51. The firm has a market cap of $57.86 million, a P/E ratio of -1.39 and a beta of 1.90. The company has a 50-day moving average price of $3.15 and a 200-day moving average price of $4.48.
Oncocyte (NASDAQ:IMDX – Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $0.56 million during the quarter.
Oncocyte Company Profile
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
See Also
- Five stocks we like better than Oncocyte
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
